Influence of Age on Incident Diabetes and Cardiovascular Disease in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
Alicia K. Morgans(Dana-Farber Cancer Institute), David F. Penson(Geriatric Research Education and Clinical Center), Peter C. Albertsen(UConn Health), Richard M. Hoffman(University of Iowa), Tatsuki Koyama(Vanderbilt University Medical Center), Janet L. Stanford, Daniel A. Barocas(Vanderbilt University Medical Center), Ann S. Hamilton(University of Southern California), Kang-Hsien Fan(Vanderbilt University), Antoinette M. Stroup(Rutgers, The State University of New Jersey), Matthew J. Resnick(Vanderbilt University Medical Center), Michael Goodman(Emory University)
Cited by 38
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694